Marketing-research budgets on the mend, survey suggests

Share this article:
Budgets of pharmaceutical marketing research teams are starting to recover, one analyst firm found.

Marketing research (MR) teams, downsized during leaner years to shield marketing and sales forces, had to endure larger staffing cuts than many other groups during the economic downturn. That's because these groups were seen largely as cost centers, says Cutting Edge Information, with no direct connection to increased revenue.

A June survey of 15 pharma companies by Cutting Edge showed both market research budgets and staffing are starting to rebound from their 2008 lows. Among small firms, dedicated MR budgets inched up, from $1.1 million in 2011 to $1.2 million this year, respondents reported. Large firms reduced budgets, from $17.3 in 2011 to $17.0 in 2012, but on average, budgets crept up, from $4.5 million to $4.7 million.

“The growth between last year and this year isn't huge,” said Elio Evangelista, director of research for the analysis firm. “But some companies are increasing their budgets by 50%; others are doubling their market-research investment.”

Overall staffing among 17 firms rose slightly, from 8.2 full-time employees in 2011 to 8.8 this year. Most companies maintained the same size, a sign MR still plays an important role.

Activities drawing more dollars include pricing, pharmacoeconomics and managed markets studies, as well as mapping out opportunities in emerging markets, said Evangelista.

One byproduct of the budget and staffing cuts was that MR teams' activities had become mostly reactive, in response to internal research requests. Dedicated funding allows MR teams to conduct ongoing and proactive research.

Still, “There really is opportunity for companies to be more proactive with their [MR] team,” Evangelista said, “to empower them more to work with key stakeholder groups, like brands teams, so they can conduct research before they're asked.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...